Septerna Inc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey T. Finer
- Full Time Employees
- 130
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 250 East Grand Avenue South San Francisco CA United States of America 94080
- IPO Date
- Oct 25, 2024
- CIK
- 0001984086
- Website
- septerna.com
- Similar Companies
- Business
- Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company that discovers and develops oral small molecule therapeutics targeting G protein-coupled receptors (GPCRs) using its proprietary, industrial-scale Native Complex Platform. The company advances a wholly owned pipeline focused initially on endocrinology, immunology and inflammation, and metabolic diseases, including SEP-479, an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) for hypoparathyroidism; SEP-631, an oral small molecule negative allosteric modulator (NAM) of MAS-related G protein-coupled receptor X2 (MRGPRX2) for chronic spontaneous urticaria and other mast cell-driven diseases; and a TSHR program featuring an oral small molecule NAM of the thyroid-stimulating hormone receptor (TSHR) for Graves' disease and thyroid eye disease. Additional research areas span neurology, women's health, cardiovascular disease, and respiratory disease; partnered metabolic programs target obesity, type 2 diabetes, and other cardiometabolic conditions via small molecule agonists of GLP-1R, GIPR, and GCGR receptors. Septerna serves patients with significant unmet needs across these therapeutic segments through novel mechanistic approaches, including agonists, antagonists, and allosteric modulators enabled by biomarker-driven strategies. Founded in 2019 and headquartered in South San Francisco, California, the company--formerly known as GPCR NewCo, Inc., with a name change in June 2021--went public on Nasdaq in October 2024. In a major strategic development, Septerna entered a global collaboration with Novo Nordisk in May 2025 to discover, develop, and commercialize multiple oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases targeting specified GPCR targets including GLP-1, GIP, and glucagon receptors; the agreement provides over $200 million in upfront and near-term payments, potential milestones exceeding $2.2 billion, tiered royalties on global net sales, and an option for Septerna to participate in worldwide profit-sharing for one program, with Novo Nordisk funding all research and development expenses post-IND-enabling activities for partnered programs. Recent pipeline progress includes dosing of the first participants in the Phase 1 clinical trial of SEP-631 in 2025 and advancement of SEP-479 and TSHR programs toward clinical stages, alongside reporting third quarter 2025 financial results that highlight a cash position extended beyond early 2028. Septerna operates primarily from the United States with no disclosed subsidiaries or parent entities.
Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
Septerna to Present at Bank of America Securities Health Care Conference
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
Septerna to Present at TD Cowen 46th Annual Health Care Conference
Septerna (NASDAQ:SEPN) Stock Price Down 5.9% on Insider Selling
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Septerna to Participate in 8th Annual Evercore Healthcare Conference
Septerna's Novo Partnership Begins To Transform The Story
Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates